{
    "id": 4926,
    "name": "bronchiolo-alveolar adenocarcinoma",
    "source": "DOID",
    "definition": "A lung adenocarcinoma characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. [url:https\\://en.wikipedia.org/wiki/Adenocarcinoma_in_situ_of_the_lung, url:https\\://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&version=16.12d&ns=NCI_Thesaurus&code=C2923, url:https\\://www.ncbi.nlm.nih.gov/pubmed/15562552, url:https\\://www.ncbi.nlm.nih.gov/pubmed/9498957]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:4926",
    "evidence": [
        {
            "id": 16635,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, EGFR T790M was identified in the post-progression lesions from a patient with bronchioloalveolar carcinoma harboring EGFR L747_A750delinsP (reported as EGFR L747_E749del; A750P) with acquired resistance to Tarceva (erlotinib) (PMID: 15737014).",
            "molecularProfile": {
                "id": 34567,
                "profileName": "EGFR L747_A750delinsP EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 4926,
                "name": "bronchiolo-alveolar adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 1879,
                    "pubMedId": 15737014,
                    "title": "Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15737014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02834013",
            "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
            "phase": "Phase 0",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        }
    ]
}